Study summary
An EGFR-HER3 antibody-drug conjugate shrank tumors in nearly half of patients
47.4%of tumors shrank
What was tested
Izalontamab brengitecan (iza-bren), a drug-carrying antibody aimed at both EGFR and HER3, in people whose cancer grew after EGFR pills. Pooled phase 1 and 2 data, no comparison group.
What they found
- Tumors shrank in 47.4%; median progression-free survival was 6.9 months.
- In people not yet given chemotherapy, median progression-free survival was 12.5 months.
- Severe side effects, mostly low blood counts, occurred in 70.2%.
What it means
Now in a phase 3 trial against chemotherapy run by Bristol Myers Squibb.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.